Evidence map›Paper›PMID 39431173›Full record

ArticleMolecular therapy. Oncology2024

AVL-armed oncolytic vaccinia virus promotes viral replication and boosts antitumor immunity via increasing ROS levels in pancreatic cancer.

Jianlei Yu, Nan An, Jili Zhu, Borong Zhu, Guohui Zhang, Kan Chen, Yanrong Zhou, Ting Ye, Gongchu Li

Abstract read
In one paragraph

Article in Molecular therapy. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Emerging interplays between poxviruses and autophagy.Frontiers in cellular and infection microbiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jianlei YuCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Nan AnCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Jili ZhuCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Borong ZhuCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Guohui ZhangCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Kan ChenCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Yanrong ZhouCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Ting YeCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Gongchu LiCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic malignant neoplasm is an extremely deadly malignancy well known for its resistance to traditional therapeutic approaches. Enhanced treatments are imperative for individuals diagnosed with pancreatic cancer (PC). Recent investigations have shed light on the wide-ranging anticancer properties of genetic therapy facilitated by oncolytic vaccinia virus. To illuminate the precise impacts of

Indexed as

antitumor efficacyMT: Regular IssueoncoVV-AVLpancreatic cancer cellsreactive oxygen speciesROSviral replication

Identifiers

PMID39431173
PMCPMC11488421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.